Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs ESPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: TLPH 1 – 5 ESPR Matrix Metrics: TLPH 4 – 6 ESPR

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin).

  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs ESPR
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 5 ESPR)

Columns: Metric · TLPH · ESPR
1. Valuation Multiples TLPH
Forward P/E 1.0x 10.9x
Trailing P/E 1.0x 4.6x
PEG Ratio N/M N/M
EV / Revenue N/M 2.2x
2. Growth & Scale ESPR
Revenue Growth (YoY) +0.0% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $418M
Market Cap $53.7M $822.0M
3. Profitability & Quality ESPR
Gross Margin N/A 57.8%
Operating Margin -1474700.0% -8.2%
Net Profit Margin 0.0% -1.8%
Return on Equity (ROE) -143.4% -260.8%
4. Balance Sheet & Cash Flow ESPR
Cash Generation (TTM) -$15M EBITDA -$18M
Cash Flow Margin N/A -4.4%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) 12.5% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ESPR
OpEx & R&D Intensity N/A 66.0% of Rev ($276M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs ESPR (6)
Institutional Metric TLPH ESPR Criterion Row Edge
Market Capitalization
Scale
$53.7M $822.0M Larger Scale ESPR
Trailing P/E Ratio
Valuation
1.0x 4.6x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 10.9x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +23.2% Higher Growth ESPR
Operating Margin (TTM)
Profitability
-1474700.0% -8.2% Higher Margin ESPR
Net Profit Margin
Profitability
0.0% -1.8% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% -260.8% Higher ROE TLPH
52-Week Range Position
Momentum
20% ($1–$2) 68% ($1–$4) Stronger Trend ESPR
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.86β · 6% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 60.0 / 100 (BUY) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $418M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 57.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$18M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +77.74 pp
TLPH: +79.01% · ESPR: +1.27%
3M Horizon TLPH +33.89 pp
TLPH: +79.76% · ESPR: +45.87%
6M Horizon TLPH +33.06 pp
TLPH: +15.87% · ESPR: -17.19%
1Y Horizon TLPH +31.62 pp
TLPH: +39.05% · ESPR: +7.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs ESPR. Trailing 12-month operating profitability (TLPH -1474700.0% vs ESPR -8.2%) and valuation multiples (TLPH 1.0x vs ESPR 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
ESPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$418M
Gross Margin57.8%
Op. Margin-8.2%
ROE / Fwd P/E-260.8% · 10.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs ESPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESPR leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with ESPR at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $418M for ESPR. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 66.0% of Rev ($276M) (0 disclosures) for ESPR.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus ESPR (-260.8% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.